Focused On-demand Library for Replication factor C subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P35249

UPID:

RFC4_HUMAN

Alternative names:

Activator 1 37 kDa subunit; Activator 1 subunit 4; Replication factor C 37 kDa subunit

Alternative UPACC:

P35249; B4DM41; D3DNV2; Q6FHX7

Background:

Replication factor C subunit 4 (RFC4), also known as Activator 1 37 kDa subunit, plays a crucial role in DNA replication and repair. It is part of the complex responsible for the elongation of primed DNA templates by DNA polymerase delta and epsilon, necessitating the action of PCNA and activator 1. This protein's involvement in the multiprimed DNA template elongation underscores its importance in cellular proliferation and genomic stability.

Therapeutic significance:

Understanding the role of Replication factor C subunit 4 could open doors to potential therapeutic strategies. Its pivotal function in DNA replication and repair mechanisms positions it as a key target for developing novel treatments aimed at enhancing genomic stability and addressing proliferative disorders.